Abstract
Background Healthcare workers (HCWs) are considered at elevated risk of experiencing mental health disorders in working with patients with COVID-19.
Aims To estimate the prevalence of common mental health disorders in HCWs based in hospitals where pandemic-affected patients were treated.
Method Databases were searched for studies published before 30th March 2020. Quantitative synthesis was used to obtain estimates of the prevalence of mental health disorders in four time windows, determined a priori (the acute phase, i.e. during and up to 1.5 months post-pandemic; 1.5-5.9 months; 6-11.9 months; 12 months and later).
Results Nineteen studies met the review criteria. They predominantly addressed the acute phase of the SARS outbreak in Asia. The most studied outcomes were clinically-significant post-traumatic stress symptoms (PTSS) and general psychiatric caseness. For clinically significant PTSS in the acute phase, the prevalence estimate was 23.4% (95% CI 16.3, 31.2; N=4147; I2=96.2%); in the 12 months plus window, the estimate was 11.9% (8.4, 15.8; N=1136; I2=74.3%). For general psychiatric caseness, prevalence estimates were: acute phase, 34.1% (18.7, 51.4; N=3971; I2=99.1%); 6-12 months, 17.9% (13.1, 23.2; N=223; I2=0.0%); 12 months plus, 29.3% (6.0, 61.0; N=710; I2=97.8%).
Conclusions Mental health disorders are particularly common in HCWs working with pandemic-afflicted patients immediately following a pandemic, but the course of disorders following this period is poorly understood. PTSS remained elevated compared to the general population at 12 months, despite there being some evidence for natural recovery. There was considerable heterogeneity, likely linked to methodological differences. More extended follow up of HCWs is needed.
Competing Interest Statement
Sophie M. Allan, Rebecca Bealey, Jennifer Birch, Toby Cushing, Sheryl Parke, Georgina Sergi and Richard Meiser-Stedman report no conflicts of interest. Michael Bloomfield is a consultant psychiatrist at the Traumatic Stress Clinic in London which is part of the UK National Health Service. Dr Bloomfield has previously undertaken consultancy work for Spectrum Therapeutics.
Funding Statement
The authors received no funding for the review.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data reported in manuscript.
